People · Operator
Named in public records as an officer, director or promoter · active 2025–2026 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CASI Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $30.0M | $12.4M | 2025 |
Barbara A. Krebs-Pohl at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Barbara A. Krebs-Pohl on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wei-Wu He | 1 | 4 |
| James A. Huang | 1 | 2 |
| David A. Cory | 1 | 2 |
| Hai Y. Huang | 1 | 1 |
| Wei (Larry) Y. Zhang | 1 | 1 |
| Chunhua Y. Wang | 1 | 1 |
| Kun Y. Qian | 1 | 1 |
| Zhenbo Su | 1 | 1 |
| Thomas Folinsbee | 1 | 1 |
| Xuebo Y. Zeng | 1 | 1 |
| Alexander Y. Wu | 1 | 1 |
| Wei Y. Gao | 1 | 1 |
| Alexander A. Zukiwski | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.